Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers (drainAD)
An Open-label, Multicenter, Controlled Pharmaco-dynamic Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease in Comparison to Healthy Volunteers
Sponsor: Immungenetics AG
Listed as NCT03417986, this PHASE2 trial focuses on Alzheimer Disease and remains completed. Sponsored by Immungenetics AG, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Mar 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Immungenetics AG
For direct contact, visit the study record on ClinicalTrials.gov .